EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback